Stent patency rates and prognostic factors of endovascular intervention for iliofemoral vein occlusion in post-thrombotic syndrome

Chen, Rencong; Feng, Ruijia; Jiang, Suiting; Chang, Guangqi; Hu, Zuojun; Yao, Chen; Jia, Benyuan; Wang, Shenming; Wang, Siwen

doi:10.1186/s12893-022-01714-9

Table 2 Patient characteristics, postoperative PTS symptoms, perioperative conditions, deep vein anatomic conditions, surgery procedures and postoperative patency rates in 22 PTS patients

From: Stent patency rates and prognostic factors of endovascular intervention for iliofemoral vein occlusion in post-thrombotic syndrome

Patient#	Time of surgery	Duration of symptoms (month)	Duration of DVT onset (month)	CEAP	Villalta score	PTS severity	Short-term postoperative Villalta score	Ulcer	preoperative anticoagulant drug	postoperative anticoagulant drug	Stenosis and occlusion severity (%)						Access veins	Location of balloon dilation	Location of stents placement	Postoperative patency
Patient#	Time of surgery	Duration of symptoms (month)	Duration of DVT onset (month)	CEAP	Villalta score	PTS severity	Short-term postoperative Villalta score	Ulcer	preoperative anticoagulant drug	postoperative anticoagulant drug	CIV	EIV	CFV	FV	PFV	PV	Access veins	Location of balloon dilation	Location of stents placement	1 m	3 m	6 m	12 m	24 m
1	2014/12/9	120	120	C5	6	Mild	6	0	0	Warfarin	100	100	70–80	50	0	50	LFV	LCIV, LEIV, LCFV	LCIV, LEIV, LCFV	P	P	P	P	P
2	2015/5/26	12	120	C2	4	Mild	4	0	Warfarin	Rivaroxaban	100	100	0	0	0	0	LFV	LCIV, LEIV	LCIV, LEIV, LCFV	P	P	P	P	P
3	2015/8/11	36	144	C6	7	Severe	6	Unhealed	Warfarin	Warfarin	< 50	100	< 50	< 50	< 50	< 50	RFV	RCIV, REIV	RCIV, REIV, RCFV	P	O(P)^a	O(P)	O(P)	O(P)
4	2016/1/12	4	10	C4	7	Mild	6	0	0	Warfarin	< 50	< 50	< 50	< 50	< 50	< 50	LGSV	LCIV, LEIV, LCFV	LCIV, LEIV, LCFV	P	P	P	P	P
5	2016/5/4	0.5	60	C4	5	Mild	3	0	Warfarin	Warfarin	100	0	0	0	0	0	LFV	LCIV, LEIV	LCIV, LEIV	O(P)	O(P)	O(P)	O(P)	O(P)
6	2016/5/6	18	18	C3	5	Mild	4	0	Rivaroxaban	Rivaroxaban	100	100	0.5–0.69	100	50–69	0	LFV	LCIV, LEIV	LCIV, LEIV	O(P)	O(O)	O(O)	O(O)	O(O)
7	2016/5/25	3	24	C4	6	Mild	4	0	Warfarin	Warfarin	< 50	100	< 30	40–60	0	40–60	RPV	RCIV, REIV, RCFV	RCIV, REIV, RCFV	P	P	P	P	P
8	2016/7/26	24	24	C1	1	Mild	1	0	Rivaroxaban	Rivaroxaban	100	100	< 50	0	0	0	LPV	LCIV, LEIV, LCFV	LCIV, LEIV	O(P)	O(P)	O(P)	O(P)	O(P)
9	2016/11/1	120	120	C6	3	Severe	2	Unhealed	0	Rivaroxaban	0	100	< 50	0	0	0	LPV	LCIV, LEIV, LCFV	LCIV, LEIV, LCFV	P	P	P	P	P
10	2016/12/16	12	12	C4	5	Mild	2	0	Rivaroxaban	Rivaroxaban	100	0	0	100	0	0	LPV	LCIV, LEIV, LCFV	LCIV, LEIV, LCFV	P	P	P	P	P
11	2017/1/10	24	24	C4	5	Mild	2	0	0	Rivaroxaban	50	50	0	0	0	0	LPV	LCIV, LEIV, LCFV	LCIV, LEIV, LCFV	P	O(O)	O(O)	O(O)	O(O)
12	2017/2/21	5	5	C6	7	Severe	7	Healed	0	Warfarin	< 50	0	< 50	< 50	0	0	LPV	LCIV, LEIV	LCIV, LEIV, LCFV	P	P	P	P	P
13	2017/6/15	48	60	C6	10	Severe	8	Healed	0	Rivaroxaban	< 50	< 50	< 50	< 50	0	< 50	LFV	LCIV, LEIV	LCIV, LEIV	P	P	P	P	O
14	2017/6/29	96	228	C6	7	Severe	5	Healed	0	Warfarin	100	100	50	0	0	0	Left tibiofibular trunk	LCIV, LEIV	LCIV, LEIV	P	P	P	O	O
15	2017/8/22	1	14	C3	2	Mild	2	0	Rivaroxaban	Rivaroxaban	100	0	0	0	0	0	LPV	LCIV, LEIV	LCIV, LEIV	O(P)	O(P)	O(P)	O(P)	O(P)
16	2018/3/12	4	84	C6	2	Severe	2	Healed	0	Rivaroxaban	50	100	30–40	60–70	0	60–70	RPV	RCIV, REIV, RCFV	RCIV, REIV, RCFV	P	P	P	P	O
17	2018/5/3	60	110	C6	10	Severe	8	Recurrent	0	Rivaroxaban	100	100	50–69	0	0	0	LPV	LCIV, LEIV, LCFV	LCIV, LEIV, LCFV	P	P	P	O(P)	O(P)
18	2018/6/19	12	12	C5	8	Mild	6	0	0	Rivaroxaban	100	100	0	0	0	0	LPV	LCIV, LEIV	LCIV, LEIV	P	P	P	P	P
19	2018/7/9	72	72	C4	10	Moderate	8	0	Warfarin	Rivaroxaban	100	100	50–75	50–100	0	< 50	LPV, RCFV	LCIV, LEIV	LCIV, LEIV, LCFV	P	P	O(P)	O(O)	O(O)
20	2018/10/23	3	60	C6	9	Severe	7	Healed	0	Rivaroxaban	100	100	60–70	100	0	100	LGSV	LCIV, LEIV	LCIV, LEIV, LCFV	P	P	O	O	O
21	2019/3/25	96	168	C6	6	Severe	6	Healed	0	Rivaroxaban	70–100	70–100	70–100	70–100	0	70–100	LPV	LCIV, LEIV, LCFV	LCIV, LEIV, LCFV	P	P	P	O(O)	O(O)
22	2019/9/16	360	360	C6	6	Severe	5	Healed	Rivaroxaban	Rivaroxaban	100	100	100	100	0	0	LPV	LCIV, LEIV, LCFV	LCIV, LEIV	P	O(P)	O(O)	O(O)	O(O)

CIV: common iliac vein; EIV: external iliac vein; CFV: common femoral vein; FV: femoral vein; PFV: profunda femoris vein; PV: popliteal vein; LCIV: left common iliac vein; RCIV: right common iliac vein; LEIV: left external iliac vein; REIV: right external iliac vein; LCFV: left common femoral vein; RCFV: right common femoral vein; LFV: left femoral vein; RFV: right femoral vein; LPV: left popliteal vein; RPV: right popliteal vein; LGSV: lift great saphenous vein; PTS: post-thrombotic syndrome; CEAP: Clinical-Etiology-Anatomy-Pathophysiology; m: months; P: patent; O: occlusion
^aPatency outcome of re-intervention

Back to article page

ISSN: 1471-2482

Contact us

Submission enquiries: bmcsurgery@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Surgery

Contact us